TICKERNERD
Menu
DTILDTILHealthcare · Biotechnology

DTIL Stock Forecast: Precision BioSciences, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$7.17
−0.97% on the day

The 5 Wall Street analysts covering Precision BioSciences, Inc. hold a median 12-month price target of $20 — +178.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 68 of 100 as at 12 Sept 2026 — in the upper half.

Market cap
$197.9M
Ticker Nerd rank
68 / 100
Median analyst target
$20
Analysts covering
5
Revenue$0.0−100.0% y/y
Operating income−$19.2M
Net income−$32.7M
Free cash flow−$13.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−2.7%
1M
−4.5%
YTD
+72.4%
1Y
+43.4%
From 52W high
−22.7%
From 52W low
+100.8%
$3.57
$9.28
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

DTIL stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Precision BioSciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
68 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
100
Momentum
81
Size
68
Accruals
65
Value
56
Quality
49
Volatility
49
Issuance
38
Revisions
31

Growth (100): Sales and profits are climbing, and climbing faster than before.

Revisions (31): Analysts have, on balance, been cutting their forecasts.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

DTIL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on DTIL, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$10.00$20.00$30.00$40.00$50.00$60.00Oct 25Jan 26Apr 26Jul 26DTILHigh $60Median $20Low $18

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
5 Buy0 Hold0 Sell
Low $18Median $20High $60

The green dot is the last close — the median target sits +178.9% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
3 Aug 2026HC Wainwright & Co.ReiteratesBuy$60
9 July 2026HC Wainwright & Co.ReiteratesBuy—
9 July 2026HC Wainwright & Co.ReiteratesBuy$60
9 June 2026OppenheimerInitiatesOutperform—
27 May 2026HC Wainwright & Co.ReiteratesBuy—
17 Apr 2026Jones TradingAssumesBuy$30
21 May 2025HC Wainwright & Co.ReiteratesBuy—
28 Mar 2025HC Wainwright & Co.ReiteratesBuy—
19 Mar 2025HC Wainwright & Co.ReiteratesBuy—
19 Feb 2025HC Wainwright & Co.ReiteratesBuy—
10 Jan 2025BMO CapitalUpgradeOutperform—
10 Jan 2025HC Wainwright & Co.ReiteratesBuy—
22 Aug 2024HC Wainwright & Co.ReiteratesBuy$60
30 May 2024HC Wainwright & Co.ReiteratesBuy—
16 May 2024HC Wainwright & Co.ReiteratesBuy—
30 Apr 2024GuggenheimInitiatesBuy—
17 Apr 2024HC Wainwright & Co.ReiteratesBuy—
28 Mar 2024HC Wainwright & Co.MaintainsBuy—
14 Feb 2024HC Wainwright & Co.ReiteratesBuy—
19 Sept 2023HC Wainwright & Co.ReiteratesBuy$3.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. DTIL appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

DTIL vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Precision BioSciences, Inc. returned +43.4% against +17.5% for the S&P 500, dividends included.

DTIL vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180200Oct 25Jan 26Apr 26Jul 26DTILS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

DTIL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
3
Fundamentals

Precision BioSciences, Inc. (DTIL) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
4.4×

Cheaper than 67% of US stocks

Price / sales
4.4×

Cheaper than 28% of US stocks

Price / book
4.2×

Cheaper than 24% of US stocks

EV / EBITDA
−3.9×

Cheaper than 77% of US stocks

Growth & margins
Revenue growth (YoY)
−100.0%

Higher than 1% of US stocks

Earnings growth (YoY)
−100.0%

Higher than 1% of US stocks

Gross margin
—
Operating margin
−80.8%

Higher than 15% of US stocks

Net margin
−117.0%

Higher than 5% of US stocks

Returns & dividend
Return on equity
−135.1%

Higher than 10% of US stocks

Return on assets
−19.4%

Higher than 20% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Precision BioSciences, Inc. (DTIL) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Precision BioSciences, Inc. has a market value of $197.9M and an enterprise value of $138.5M.

  • Revenue in the twelve months to 30 June 2026: $45.1M. The latest quarter shrank 100.0% year on year.

  • Net income over the same four quarters: −$52.7M, a −117.0% net margin.

  • Diluted earnings per share, trailing twelve months: $−2.80.

  • Free cash flow in the twelve months to 30 June 2026: −$52.4M.

  • Shares outstanding: 26.4M.

  • Trailing P/E: 4.4×; forward P/E: −3.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Precision BioSciences, Inc. employs 67 people — $672K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 14 Sept 2026

Data provided by Twelve Data

Peers

DTIL vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
DTILPrecision BioSciences, Inc.$197.9M
68
ARMPArmata Pharmaceuticals, Inc.$197.1M
71
CHRSCoherus Oncology, Inc.$198.8M
52
KRROKorro Bio, Inc.$199.2M
29
ANTXAN2 Therapeutics, Inc.$194.4M
72
NERVMinerva Neurosciences, Inc.$193.3M
32
TNXPTonix Pharmaceuticals Holding Corp.$203.6M
27

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Precision BioSciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest DTIL news & analysis

Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study

Business Wire · 24 Aug 2026positive

Precision BioSciences announced that the first patient was dosed in August in its Phase 1/2 FUNCTION-DMD clinical trial, which evaluates PBGENE-DMD for the treatment of Duchenne muscular dystrophy. PBGENE-DMD is the company's wholly owned in vivo gene editing program built on its ARCUS platform.

Why it matters — This marks an important clinical milestone for Precision's lead wholly owned in vivo gene editing program, advancing it into patient evaluation for a serious unmet-need disease.

Precision BioSciences: Promising HBV Editing Evidence

Seeking Alpha · 18 Aug 2026positive

Precision BioSciences' PBGENE-HBV liver biopsy data provides direct evidence that its ARCUS platform is editing the viral reservoir in patients, though durable off-treatment viral control remains unproven and the program lacks disclosed human safety or efficacy data. The next ELIMINATE-B updates are seen as decisive for the investment thesis, with PBGENE-DMD offering a second validation path.

Why it matters — A DTIL watcher would care because the liver biopsy data offers early direct evidence of ARCUS editing in patients, while upcoming ELIMINATE-B updates could determine whether the HBV program delivers durable viral control.

Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Business Wire · 6 Aug 2026positive

Precision BioSciences, a clinical-stage gene editing company, reported its financial results for the second quarter ended June 30, 2026, and provided a business update. The company stated that the quarter marked a defining moment for Precision BioSciences and the hepatitis B field, citing the first clinical biopsy evidence that a therapeutic.

Why it matters — The update highlights a notable clinical milestone for the company's hepatitis B therapy, which DTIL watchers would track as a key development for the pipeline.

Precision BioSciences Announces Changes to Senior Leadership Team to Support Advancement of Programs Through Next Set of Clinical Milestones

Business Wire · 27 July 2026neutral

Precision BioSciences announced changes to its senior leadership team, including the promotion of Chief Financial Officer Alex Kelly to the newly created role of Chief Operating Officer, overseeing customer-facing functions.

Why it matters — Leadership changes at a clinical-stage biotech signal how the company is positioning itself to execute on upcoming clinical milestones for its gene editing pipeline.

FAQ

Frequently asked questions about DTIL stock

What is the DTIL stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Precision BioSciences, Inc. have a median 12-month price target of $20, with estimates ranging from $18 to $60. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is DTIL stock a buy right now?

Of the 5 analysts covering Precision BioSciences, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Precision BioSciences, Inc. 68 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank DTIL?

As at 12 Sept 2026, Precision BioSciences, Inc. ranks 68 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (100 of 100).

Will DTIL stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +178.9% from the last close, and Ticker Nerd's factor model ranks Precision BioSciences, Inc. 68 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the DTIL stock forecast for 2030?

No analyst covering Precision BioSciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DTIL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $18 to $60 over the next 12 months.

How has DTIL stock performed over the past year?

Precision BioSciences, Inc. returned +43.4% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Precision BioSciences, Inc. do?

Precision BioSciences, Inc. is a clinical-stage gene editing company focused on developing in vivo therapies for serious diseases with limited treatment options.

What is the latest news on DTIL?

The most recent item we track (Business Wire, 24 Aug 2026): "Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study". Precision BioSciences announced that the first patient was dosed in August in its Phase 1/2 FUNCTION-DMD clinical trial, which evaluates PBGENE-DMD for the treatment of Duchenne muscular dystrophy. PBGENE-DMD is the company's wholly owned in vivo gene editing program built on its ARCUS platform.

Company

About Precision BioSciences, Inc.

Precision BioSciences, Inc. is a clinical-stage gene editing company focused on developing in vivo therapies for serious diseases with limited treatment options. Its proprietary ARCUS® genome editing platform is designed to make precise changes to DNA and supports programs aimed at treating chronic hepatitis B, Duchenne muscular dystrophy, and other high-unmet-need conditions. The company’s current work centers on advancing therapeutic candidates through clinical development, with an emphasis on direct gene correction, elimination, or insertion in targeted tissues. Precision BioSciences serves the biotechnology and life sciences markets by applying its editing technology to human therapeutics, positioning itself as a specialist in next-generation genetic medicine from its headquarters in Durham, North Carolina.

CEO Mr. Michael Amoroso · 67 employees · United States · https://precisionbiosciences.com